ReviewScience China. Life sciences2025
Unlocking lignin valorization and harnessing lignin-based raw materials for bio-manufacturing.
Review in Science China. Life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Ectoine Mitigates Stress and Enhances Lignin to Vanillin Bioconversion in Halalkalibacterium ligniniphilum L1.ChemSusChem · 2026Article
- Development of SpyTag/SpyCatcher-driven thermostable cyclic laccase and its application in lignin and dye degradation and polymerization of phenolic compounds.Science China. Life sciences · 2026Article
- Biosynthesis of melanin from lignin hydrolysates by metabolically engineered Cupriavidus necator.Science China. Life sciences · 2026Article
- From Lignocellulosic Residues to Protein Sources: Insights into Biomass Pre-Treatments and Conversion.Polymers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lignin, an energy-rich and adaptable polymer comprising phenylpropanoid monomers utilized by plants for structural reinforcement, water conveyance, and defense mechanisms, ranks as the planet's second most prevalent biopolymer, after cellulose. Despite its prevalence, lignin is frequently underused in the process of converting biomass into fuels and chemicals. Instead, it is commonly incinerated for industrial heat due to its intricate composition and resistance to decomposition, presenting obstacles for targeted valorization. In contrast to chemical catalysts, biological enzymes show promise not only in selectively converting lignin components but also in seamlessly integrating into cellular structures, offering biocatalysis as a potentially efficient pathway for lignin enhancement. This review comprehensively summarizes cutting-edge biostrategies, ligninolytic enzymes, metabolic pathways, and lignin-degrading strains or consortia involved in lignin degradation, while critically evaluating the underlying mechanisms. Metabolic and genetic engineering play crucial roles in redirecting lignin and its derivatives towards metabolic pathways like the tricarboxylic acid cycle, opening up novel avenues for its valorization. Recent advancements in lignin valorization are scrutinized, highlighting key challenges and promising solutions. Furthermore, the review underscores the importance of innovative approaches, such as leveraging digital systems and synthetic biology, to unlock the commercial potential of lignin-derived raw materials as sustainable feedstocks. Artificial intelligence-driven technologies offer promise in overcoming current challenges and driving widespread adoption of lignin valorization, presenting an alternative to sugar-based feedstocks for bio-based manufacturing in the future. The utilization of available lignin residue for synthesis of high-value chemicals or energy, even alternative food, addresses various crises looming in the food-energy-water nexus.
Indexed as
Identifiers
39704933What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.